Head-to-head evidence
Daratumumab vs Mezagitamab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
Daratumumab
Marketed by Johnson & Johnson
NCT02076009 · Phase 3 · completed
This was a large randomized, open-label trial with an active comparator, enrolling 286 participants in the daratumumab group and 283 in the control group. Progression-free survival was the hard clinical primary endpoint, but the registry does not report a complete treatment comparison or statistical significance for it, so the result cannot be clearly classified as met.
Next expected readout: October 2026 · NCT06140966 (registry estimate)
Mezagitamab
Developed by Takeda Pharmaceutical Company
NCT03439280 · Phase 1/2 · completed
This was a nonrandomized, open-label, single-arm dose-escalation study of 50 participants, with no placebo or active comparator. Its primary outcomes focused on safety, including treatment-emergent adverse events and dose-limiting toxicities, rather than a controlled efficacy comparison; 50 of 50 participants reported at least one treatment-emergent adverse event, and 1 of 41 dose-limiting-toxicity-evaluable participants had a dose-limiting toxicity.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Daratumumab's landscape · Mezagitamab's landscape